Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21 ^st century

Population-level survival has increased for a number of hematologic malignancies.1–3 Multiple myeloma, in particular, has seen improved survival both in clinical trials4–8 and on the population level.3,9–11 However, it is not known whether the changes in survival for myeloma have extended to other, less common plasma cell or plasmacytoid malignancies such as lymphoplasmacytic lymphoma (LPL, includes Waldenström’s macroglobulinemia (WM)), plasma cell leukemia (PCL), and solitary plasmacytoma (SP). Only a few population level studies of survival are available on LPL,12,13 PCL,14,15 and SP,16 with little information on changes in survival in the past decade.

...